Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa is under clinical development by Holostem Terapie Avanzate and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II drugs for Epidermolysis Bullosa have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GlobalData
Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa

Buy the report

Related Company Profiles

View All

Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa overview

Gene therapy is under development for the treatment of junctional epidermolysis bullosa (JEB). It consists of autologous cultured epidermal grafts containing epidermal stem cells genetically modified with the aid of a retroviral vector carrying LAMB-3 cDNA. It is administered through cutaneous route.

For a complete picture of Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.